Udenyca (Pegfilgrastim-Cbqv) Drug Interactions: 5 Moderate
Udenyca (Pegfilgrastim-Cbqv) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Udenyca. Always confirm against the full prescribing information.
19 interactions
Cyclophosphamide
The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.
Level 1 evidence
Topotecan
The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.
Level 1 evidence
Vinblastine
The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinblastine.
Level 2 evidence
Vincristine
The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine.
Level 2 evidence
Vinorelbine
The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinorelbine.
Level 2 evidence
Certolizumab pegol
The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegfilgrastim.
Level 2 evidence
Damoctocog alfa pegol
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegfilgrastim.
Level 2 evidence
Elapegademase
The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.
Level 2 evidence
Methoxy polyethylene glycol-epoetin beta
The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.
Level 2 evidence
Pegaspargase
The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.
Level 2 evidence
Peginterferon alfa-2a
The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.
Level 2 evidence
Peginterferon alfa-2b
The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.
Udenyca (Pegfilgrastim-Cbqv) has 19 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Udenyca (Pegfilgrastim-Cbqv) has 0 major, 5 moderate, and 14 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Udenyca. Always confirm against the full prescribing information.